Americans Are Cutting Spending on Everything Except Healthcare.
These 2 Medical Device Stocks Under $30 Are Built to Win Quick Read – Envista (NVST) posted Q1 FY26 revenue of $705.5M growing 14.4% year-over-year with adjusted EPS of $0.36 topping estimates by 14.94%, while management reaffirmed full-year guidance of $1.35 to $1.45 and authorized a $300M share buyback through December 31, 2029
Bausch & Lomb (BLCO) reported Q1 FY26 revenue of $1.244B up 9.4% year-over-year and swung to $33M in operating income from a $83M loss, with pharmaceuticals segment MIEBO and XIIDRA growing 33% and 30% respectively, driving management to raise full-year revenue guidance to $5.420B to $5.520B and adjusted EBITDA to $1.010B to $1.060B. – Rising personal healthcare spending at $3.741.3B through March 2026 outpacing total consumption growth is making defensive medical device names attractive to retail investors as consumer sentiment languishes at 53.3 in pessimistic territory. – The analyst who called NVIDIA in 2010 just named his top 10 stocks and Bausch & Lomb wasn’t one of them. Get them here FREE. With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets.
Healthcare keeps that promise. Personal healthcare spending climbed from $3.432 trillion in January 2025 to $3.741 trillion by March 2026, outpacing total consumption while motor vehicles and other discretionary categories softened. Medical device stocks trading below $30 give individual investors an affordable way to ride that resilience.